ClinicalTrials.gg
Not yet recruitingNCT06268054LIBERTÀUpdated Feb 22, 2024

Efficacy and Safety of DEH113 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea

A Phase 3 interventional study of DEH113 and Placebo Comparator in Primary Dysmenorrhea, sponsored by EMS. Not yet recruiting. Open to female participants aged 16 Years to 35 Years. Per ClinicalTrials.gov, last updated 2024-02-22.

Sponsored by EMS · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
16 Years to 35 Years
Sex
Female
01

Study summary

The purpose of this study if to evaluate the efficacy and safety of DEH113 in the Treatment of Menstrual Cramp Pain Associated With Primary Dysmenorrhea.

02

Conditions studied

  • Primary Dysmenorrhea

Browse trials for

03

In context

Dysmenorrhea

432 studies on the registry are indexed under Dysmenorrhea; 109 are open to participants now.

This study's planned enrollment of 78 is above the median of 62 across 364 interventional studies indexed under Dysmenorrhea.

Browse Dysmenorrhea studies →

Lead sponsor

EMS is the lead sponsor of 84 studies on the registry; 21 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has given written to participate in the study prior to admission to the study;
  • Female patients aged between 16 and 35 years old, inclusive;
  • History of regular menstrual cycles, occuring between every 21 to 35 days;
  • Clinical history compatible with the diagnosis of primary dysmenorrhea;
  • Self-reported history of ≥ 4 painful cycles, with moderate or severe menstrual cramps, in the six (06) months prior to selection for the study.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of secondary dysmenorrhea;
  • History of non-response to treatment with non-steroidal anti-inflammatory drugs (NSAIDs) to relieve menstrual cramps;
  • Onset of primary dysmenorrhea after starting to use oral ;
  • Use of oral contraceptives for \< 4 months prior to study selection;
  • Use of an intrauterine device (IUD), hormonal implants or contraceptive injections in the last six (06) months;
  • Previous diagnosis or physical examination findings and/or clinical and/or surgical history that may indicate the presence of endometriosis, pelvic inflammatory disease, adenomyosis, mullerian duct malformation, uterine fibroma, cystic ovary and/or pelvic varicocele;
  • History of recurrent pelvic and/or lower abdominal pain outside the menstrual period;
  • Presence of known allergy or to the components of the drugs used during the clinical trial;
  • History of hypersensitivity reactions, such as asthma attacks or other types of allergic reactions, to acetylsalicylic acid or other NSAIDs;
  • Previous diagnosis of glaucoma;
  • Previous diagnosis of kidney and/or liver failure;
  • Presence of blood dyscrasias and situations of bone marrow suppression;
  • Diagnosis of acute intermittent hepatic porphyria;
  • Diagnosis of congenital deficiency of glucose-6-phosphate dehydrogenase (G6PD);
  • Presence of mechanical stenosis in the gastrointestinal tract;
  • Previous diagnosis of paralytic ileus or intestinal atony
  • Diagnosis of myasthenia gravis;
  • Previous diagnosis of severe ulcerative colitis or toxic megacolon complicated with ulcerative colitis
  • Participants with a history of alcohol or illicit drug use disorder in the last two (02) years;
  • Participants with a current medical history of cancer and/or cancer treatment in the last five (05) years;
  • Any finding of clinical observation (clinical/physical evaluation) or laboratory condition that is interpreted by the investigating physician as a risk to the participation of the research participant in the clinical trial or presence of uncontrolled chronic disease(s);
  • Participants who are pregnant, nursing or planning to become pregnant;
  • Disagreement with the use of a known effective barrier contraceptive method, unless using a stable oral contraceptive for three months or more (which must be maintained throughout the study), or surgically sterile or who expressly declare themselves exempt from risk of pregnancy for not exercising sexual practices or exercising them in a non-reproductive manner;
  • Participation in a clinical research protocol in the last 12 months (CNS Resolution 251, of August 7, 1997, item III, subitem J), unless the investigator judges that there may be a direct benefit to it;
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
78 participants (estimated)

Study arms

  • Experimental
    DEH113

    The patient must take two (2) DEH113 tablets, if pain, up to three times a day.

    Drug: DEH113

  • Placebo comparator
    Control

    The patient must take two (2) DEH113 placebo tablets, if pain, up to three times a day.

    Drug: Placebo Comparator

Interventions

  • DrugDEH113

    Tablets

  • DrugPlacebo Comparator

    Tablets

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Sum of Total Pain Relief (TOTPAR) over 0-6 hours post-dose

    Pain relief will be evaluated considering the Sum of Total Pain Relief (TOTPAR) over 0-6 hours post-dose. Pain relief will be evaluate using a Categorical Pain Relief Rating Scale (0 = No relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief).

    Time frame: 6 hours post-dose

Secondary outcomes

  1. Sum of Total Pain Relief (TOTPAR) over 0-4 and 0-8 hours post-dose

    Pain relief will be evaluated considering the Sum of Total Pain Relief (TOTPAR) over 0-4 and 0-8 hours post-dose. Pain relief will be evaluate using a Categorical Pain Relief Rating Scale (0 = No relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, 4 = complete relief).

    Time frame: 4 and 8 hours post-dose

  2. Sum of Pain Intensity Difference (SPID) over 4, 6 and 8 hours post-dose.

    Sum of Pain Intensity Difference (SPID) over 4, 6 and 8 hours post-dose. The pain intensity will be assessed using a Categorical 4-point scale (0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain).

    Time frame: 4, 6 and 8 hours post-dose

  3. Use of rescue medication

    Proportion of participants who used rescue medication in the first 24 hours after the first drug intake, amount of rescue medication used in the first 24 hours after the first drug intake, and time elapsed between the last drug intake and the first administration of rescue medication.

    Time frame: 24 hours post-dose

  4. Number of additional drug intake

    Number of additional drug intake during the 24 hours after the first drug intake

    Time frame: 24 hours post-dose

  5. Patients' Global Impression of Change (PGIC)

    Patients' Global Impression of Change (PGIC) will be assessed after 8 hours post-dose or immediately before the intake of rescue medication.

    Time frame: 8 hours post-dose

  6. Incidence of Adverse Events Associated with DEH113 in the Treatment of Primary Dysmenorrhea

    The safety will be evaluated considering the incidence of adverse events (AEs) reported during the study period.

    Time frame: 7 days post dose

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2025; primary completion for Feb 2027, 24 months later.

Of 17 phase 3 interventional studies under Dysmenorrhea, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 30. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2024
First posted
Feb 20, 2024
StartEst.
Feb 2025
Primary completionEst.
Feb 2027
CompletionEst.
Sep 2027
Last update
Feb 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06268054
Lead sponsor
EMS
Responsible party
Sponsor
First posted
Feb 20, 2024
Start date
Feb 2025 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Feb 22, 2024

Study contacts

Alexandra FD Alves, MSc
Contact
pesquisa.clinica@ncfarma.com.br
+551938878917

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion